Aravive Biologics, Inc. has been honored as the 2017 “Innovator of the Year” by YTEXAS, which hosted its 4th Annual YTEXAS RēLO AWARDS on September 29, 2017.
“The RēLO AWARDS honor the “Featured 50” – the most notable corporate relocations from the previous 5 years that embody the three tenets of the YTEXAS mission; community, commerce and culture,” said Ed Curtis, Chief Executive Officer of YTEXAS. “We are pleased to honor Aravive Biologics as our 2017 Innovator of the Year in recognition of the potential that their approach to the treatment of cancer offers for improving therapy for many people with such disease.”
“We are very pleased to receive this recognition from YTEXAS and appreciate their support since we relocated to Houston in the past year,” said Stephen L. Eck, M.D., Ph.D., President and Chief Executive Officer of Aravive Biologics. “We have found great talent in Texas, as well as the resources to help our company grow. Moreover, the support we have received from the Cancer Prevention & Research Institute of Texas (CPRIT) has been instrumental in helping us accelerate the development of potential therapeutics and contribute to the healthcare industry through new job creation and collaborations with local hospitals and universities. We are very pleased to have become a Texas company and look forward to growing and succeeding here over the coming years.”
“Thanks in part to Governor Abbott’s leadership, the Cancer Prevention Research Institute of Texas continues to serve as a critical resource for companies like Aravive Biologics who are on the cutting edge of cancer research in Texas,” said Robert Allen, President and CEO, Texas Economic Development Corporation.
About YTEXAS and the RēLO Awards
YTEXAS is an organization that accelerates CEO connectivity and corporate presence for companies that are newly relocated to Texas.
The RēLO Awards are bestowed upon companies that have relocated corporate headquarters to Texas over the previous 5 years. The award categories include Gamechanger, Innovator, and Texas All-in. One Texas-based CEO is awarded Ambassador of the Year for his/her commitment to assisting these companies, both personally and professionally, in their transition into Texas. The awards and Featured 50 companies are voted upon by a select group of seasoned Texas CEOs.
CPRIT provides funding through its academic research, prevention and product development research programs. In 2007, Texas voters approved a constitutional amendment to establish CPRIT with $3 billion in bonds. Since 2009, CPRIT has presented 1,189 grants totaling roughly $1.89 billion to support cancer research, product development and prevention programs. During the 85th Texas Legislature, CPRIT’s Sunset Review date was extended by two years to 2023 to allow the agency to fulfill its constitutional mandate to invest all funds approved by Texas voters. Programs made possible with CPRIT funding have reached all 254 counties of the state; brought more than 135 distinguished researchers to Texas; advanced scientific and clinical knowledge; and provided more than 3.9 million life-saving education, training, prevention and early detection services to Texans.
About Aravive Biologics, Inc.
Aravive Biologics is a privately held, late pre-clinical stage biopharmaceutical company developing novel, highly selective cancer therapies that treat serious malignancies while sparing normal healthy cells. The company’s lead program is focused on the GAS6/AXL pathway, where activation appears to play a critical role in multiple types of cancer malignancies by promoting tumor metastasis and cell survival. Aravive Biologics has generated strong preclinical data for its lead drug candidate, Aravive-S6, in both acute myeloid leukemia (AML) and solid tumors including ovarian, pancreatic, and breast cancers. The company is based in Houston, Texas, and receives support from the Cancer Prevention & Research Institute of Texas (CPRIT). For more information, please visit our website at http://www.aravive.com.